Bangalore based pharmaceutical company; Strides Acrolab has announced that it has received the approval by the US Food and Drug Administration to manufacture its antibacterial drug Polymyxin B while its Oral Dosage Oncology facility in Bangalore has also received the European approval.
Strides, which already manufactures and supplies over 25 injectable products in the American market, said that it has received the approval from the FDA to supply Polymyxin B which will be marketed through Sagent.
The Onco Therapies Limited, a division of Agila which is a wholly owned subsidiary of Strides, revealed that its Oral Dosage Oncology facility for tablet and hard gelatine capsules has been approved by the European regulators, making it one of the few European approved Oral dosage oncology plants in the world.
Commenting on the European approval, the CEO of Agila, Venkat Iyer said, "We are delighted with this development as this further consolidates our global strategy of emerging as a leading provider of oncology drugs. The approval is also a testimony to the high standards of quality, compliance and containment practices put in place by Strides".
Strides also revealed that it will be introducing two new products in the European market by the end of the third quarter.